Gentris Joins Personalized Medicine Coalition
News Dec 09, 2005
Gentris Corporation has announced that the company has joined the Personalized Medicine Coalition (PMC).
The PMC was founded in 2003 by 20 leading pharmaceutical, biotechnology, diagnostics and information technology companies, along with major academic centers and governmental agencies.
The Coalition seeks to promote discussion and understanding that will lead to the development of sound public policy on matters that affect the realization of personalized medicine.
"The Coalition brings together leaders from every sector involved in personalized medicine. Together we will educate and explore issues that may require new or revised public policy," commented Michael Murphy, President and CEO of Gentris.
"We are excited to be a part of a group that will have a profound effect on the medical treatments that are currently used, and those still to be discovered."
Edward Abrahams, Executive Director of the PMC, sees Gentris as an integral member of the Coalition whose mission it is to advance personalized medicine in the public arena.
"Gentris' leadership in promoting pharmacogenomics can provide invaluable guidance and experience to our members and our mission," commented Abrahams.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.